Skip to main content
. 2015 May 30;20(4):259–272. doi: 10.1016/j.rpor.2015.04.003

Table 2.

Drugs under investigation in patients with CRPC, with and without metastasis.

CRPC without metastasis
- VANDETANIB ± BICALUTAMIDE
- ZIBOTENTAN vs. PLACEBO
- Enzalutamide-MDV3100 vs. PLACEBO (PROSPER)
- ORTERONEL		 Tyrosine-kinase inhibitor, antagonist of vascular endothelial growth factor and epidermal growth factor.
Endothelin A inhibitor.
Androgen receptor antagonist.
Selective 17–20 lyase-inhibitor.
CRPC with metastasis
Closed phase 3 studies -DOCETAXEL/PREDNISONA ± CALCITRIOL
- DOCETAXEL/PREDNISONA ± BEVACIZUMAB		 ASCENT-2: no differences in OS
CALGB 90401: no differences in OS
New Drugs - LENALIDOMIDE
- AFLIBERCEPT
- AAFTERENTAN
- ZIBOTENTAN
- DASATINIB
- CURTISEN		 Angiogenesis inhibitor
Angiogenesis inhibitor
Endothelin A inhibitor
Endothelin A inhibitor
Tyrosine kinase inhibitor
Clusterin inhibitor